Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
|Videos|August 6, 2021
Dr. Pieczonka on initial efficacy and safety data for sabizabulin (VERU-111) in mCRPC
Author(s)Urology Times staff
Advertisement
Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses phase 2 data for the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in metastatic castration-resistant prostate cancer (mCRPC) presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi:10.1200/JCO.2021.39.15_suppl.5056). He also discusses toxicity differences between VERU-111 and docetaxel.
According to Pieczonka, additional phase 2 data for VERU-111 will be shared in September at the upcoming 2021 ESMO Annual Meeting. A phase 3 trial (NCT04844749) of VERU-111 in mCRPC has already been launched.
Advertisement
Related to this article
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
Survey: Service members and veterans with NMIBC report barriers to treatment access
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5